In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: The activity of the double-carbapenem regimen is related to meropenem MIC value

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 7, 2017, Pages 1981-1984

  Oliva, A ^a   Scorzolini, L ^a   Cipolla, A ^a   Mascellino, M T ^a   Cancelli, F ^a   Castaldi, D ^a   D'Abramo, A ^a   D'Agostino, C ^a   Russo, G ^a   Ciardi, M R ^a   Mastroianni, C M ^a   Vullo, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEMASE; COLISTIN; DORIPENEM; ERTAPENEM; GENTAMICIN; MEROPENEM; RIFAMPICIN; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; THIENAMYCIN DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SCREENING; IN VITRO STUDY; INFECTION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; BIOSYNTHESIS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DRUG EFFECTS; ENZYMOLOGY; EVALUATION STUDY; HUMAN; KLEBSIELLA INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; THIENAMYCINS;

EID: 85021804499     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx084     Document Type: Article

References (20)

1. Munoz-Price LS, Poirel L, Bonomo RA et al. Clinical epidemiology of the global expansion of K. pneumoniae carbapenemases. Lancet Infect Dis 2013; 13: 785-96.
2. Tumbarello M, Viale P, Viscoli C et al. Predictors ofmortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55: 943-50.
3. Tascini C, Tagliaferri E, Giani T et al. Synergistic activity of colistin plus rifampicin against colistin-resistant KPC-producing K. pneumoniae. Antimicrob Agents Chemother 2013; 57: 3990-3.
4. Ah YM, Kim AJ, Lee JY. Colistin resistance in K. pneumoniae. Int J Antimicrob Agents 2014; 44: 8-15.
5. Capone A, Giannella M, Fortini D et al on behalf of the SEERBIO-GRAB network. High rate of colistin resistance among patients with carbapenemresistant Klebsiella pneumoniae infection accounts for an excess ofmortality. Clin Microbiol Infect 2013; 19: E23-30.
6. Oliva A, Gizzi F, Mascellino MT et al. Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemaseproducing Klebsiella pneumoniae. ClinMicrobiol Infect 2016; 22: 147-53.
7. Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemaseproducing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011; 55: 3002-4.
8. Giamarellou H, Galani L, Baziaka F et al. Effectiveness of a doublecarbapenem regimen for infections in humans due to carbapenemaseproducing pandrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2013; 57: 2388-90.
9. Oliva A, D'Abramo A, D'Agostino C et al. Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections. J Antimicrob Chemother 2014; 69: 1718-20.
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
11. Yoon J, Urban C, Terzian C et al. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004; 48: 753-7.
12. Jernigan MG, Press EG, Nguyen MH et al. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase- producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2012; 56: 3395-8.
13. Petrosillo N, Giannella M, Lewis R et al. Treatment of carbapenemresistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther 2013; 11: 159-77.
14. Pogue JM, Lee J, Marchaim D et al. Incidence and risk factors for colistinassociated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53: 879-84.
15. Satlin MJ, Kubin CJ, Blumenthal JS et al. Comparative effectiveness of aminoglycosides, polymyxin B and tigecycline for clearance of carbapenemresistant K. pneumoniae from urine. Antimicrob Agents Chemother 2011; 55: 5893-9.
16. Garbati MA, Al Godhair AI. The growing resistance of Klebsiella pneumoniae; the need to expand our antibiogram: case report and review of the literature. Afr J Infect Dis 2013; 7: 8-10.
17. Gaibani P, Lombardo D, Lewis RE et al. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistinresistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother 2014; 69: 1856-65.
18. Conrad RS, Gilleland HE Jr. Lipid alterations in cell envelopes of polymyxin-resistant Pseudomonas aeruginosa isolates. J. Bacteriol 1981; 148: 487-97.
19. Oliva A, Scorzolini L, Castaldi D et al. Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp). J Infect 2017; 74: 103-6.
20. Ceccarelli G, Oliva A, d'Ettorre G et al. The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit. BMC Infect Dis 2015; 15: 393.